Amgen (AMGN) Tops Q2 EPS by 69c, Beats on Revenue; Offers FY26 Guidance
Tweet
Share
E-mail
Get Alerts AMGN Hot Sheet
Price: $395.18 -9.62%
Revenue Growth %: +5.1%
Financial Fact:
Other charges: 23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.1%
Financial Fact:
Other charges: 23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported Q2 EPS of $6.29, $0.69 better than the analyst estimate of $5.60. Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.43 billion.
GUIDANCE:
Amgen sees FY2026 EPS of $22.30-$23.50, versus the consensus of $22.35. Amgen sees FY2026 revenue of $38.2-39.4 billion, versus the consensus of $37.7 billion.
For earnings history and earnings-related data on Amgen (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Activist investor presses Xerox to review financial services arm - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
